Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials

[1]  B. Ascher,et al.  Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study , 2021, Aesthetic surgery journal.

[2]  Yan Liu,et al.  Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection , 2021, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[3]  J. Schlessinger,et al.  AbobotulinumtoxinA Treatment of Glabellar Lines Using a New Reconstitution and Injection Volume: Randomized, Placebo-Controlled Data. , 2021, Journal of drugs in dermatology : JDD.

[4]  B. Kim,et al.  Efficacy and Safety of a New Botulinum Toxin (HU-014) Versus Existing Onabotulinumtoxin A in Subjects With Moderate to Severe Glabellar Lines. , 2020, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[5]  C. Maas,et al.  A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines , 2020, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[6]  C. Maas,et al.  IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines. , 2020, Journal of drugs in dermatology : JDD.

[7]  L. Baumann,et al.  DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study , 2020, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[8]  C. Maas,et al.  A Double-Blind, Randomized Clinical Trial to Determine Effects of Increasing Doses and Dose-Response Relationship of IncobotulinumtoxinA in the Treatment of Glabellar Rhytids. , 2020, Aesthetic surgery journal.

[9]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[10]  M. Kawashima,et al.  Safety, Efficacy, and Patient Satisfaction With OnabotulinumtoxinA for the Treatment of Upper Facial Lines in Japanese Subjects. , 2020, Dermatologic Surgery.

[11]  J. Carruthers,et al.  DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2) , 2019, Plastic and reconstructive surgery.

[12]  J. Schlessinger,et al.  DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). , 2019, Journal of the American Academy of Dermatology.

[13]  Joel L Cohen,et al.  Clinical Assessment of 2 Licensed AbobotulinumtoxinA Injection Volumes for the Treatment of Glabellar Lines. , 2019, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[14]  Ruilian Li,et al.  Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trial , 2019, Journal of immunology research.

[15]  M. Kerscher,et al.  Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines , 2019, Aesthetic surgery journal.

[16]  C. Maas,et al.  Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines. , 2019, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[17]  D. Vitarella,et al.  Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin, in Subjects with Glabellar Frown Lines: Results of a Phase 2, Randomized, Placebo-Controlled, Ascending-Dose Study , 2018, Plastic and reconstructive surgery.

[18]  I. Carlisle,et al.  Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport®/Azzalure®): Primary Results of the APPEAL Noninterventional Study , 2018, Aesthetic Plastic Surgery.

[19]  B. Rzany,et al.  Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial , 2018, Aesthetic surgery journal.

[20]  J. Carruthers,et al.  Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines: Additional Analyses From a Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Study , 2017, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[21]  J. Carruthers,et al.  Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines: A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and Placebo , 2017, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[22]  T. Alster,et al.  A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines , 2015, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[23]  Yongzhou Lu,et al.  Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Glabellar Lines: A Meta-Analysis of Randomized, Placebo-Controlled, Double-Blind Trials , 2015, Plastic and reconstructive surgery.

[24]  Kristian Thorlund,et al.  The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.

[25]  Su-Young Lee,et al.  Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: A multicenter, randomized, double‐blind, active‐controlled study , 2015, International journal of dermatology.

[26]  H. Kwon,et al.  Double‐blind, randomized non‐inferiority trial of a novel botulinum toxin A processed from the strain CBFC26, compared with onabotulinumtoxin A in the treatment of glabellar lines , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[27]  J. Schlessinger,et al.  A Randomized, Placebo‐Controlled, Double‐Blind Phase III Trial Investigating the Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines Using a Stringent Composite Endpoint , 2013, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[28]  J. Carruthers,et al.  Multicenter, Randomized, Phase III Study of a Single Dose of IncobotulinumtoxinA, Free from Complexing Proteins, in the Treatment of Glabellar Frown Lines , 2013, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[29]  K. Hoffmann,et al.  A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines , 2012, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[30]  B. Rzany,et al.  Noninferiority of IncobotulinumtoxinA, Free from Complexing Proteins, Compared with Another Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines , 2010, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[31]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[32]  N. Swanson,et al.  Randomized, Placebo‐Controlled Study of a New Botulinum Toxin Type A for Treatment of Glabellar Lines: Efficacy and Safety , 2009, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].